Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

This study has been completed.

Sponsor:

Information provided by:

Hvidovre University Hospital

ClinicalTrials.gov Identifier:

NCT00999271

First received: October 20, 2009

Last updated: NA

Last verified: October 2009

History: No changes posted

Tracking Information
First Received Date ^ICMJE	October 20, 2009
Last Updated Date	October 20, 2009
Start Date ^ICMJE	August 2008
Primary Completion Date	September 2009 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
Official Title ^ICMJE	On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans
Brief Summary	The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case Control
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	Healthy volunteers
Condition ^ICMJE	Healthy Subjects
Intervention ^ICMJE	Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP) two different dosages: 0.8 pmol/kg/min 1.5 pmol/kg/min for 300 minutes
Study Group/Cohort (s)	Healthy subjects 30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine Intervention: Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	30
Completion Date	September 2009
Primary Completion Date	September 2009 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Informed oral and written consent Caucasians over the age of 18 years Normal 75 g oral glucose tolerance test (OGTT) Normal blood haemoglobin concentration Normal plasma lipid profile Exclusion Criteria: First-degree relatives with diabetes and familial hypertriglyceridemia
Gender	Male
Ages	18 Years to 50 Years
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Denmark

Administrative Information
NCT Number ^ICMJE	NCT00999271
Other Study ID Numbers ^ICMJE	HD-2009-0025
Has Data Monitoring Committee	No
Responsible Party	University of Copenhagen
Study Sponsor ^ICMJE	Hvidovre University Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Hvidovre University Hospital
Verification Date	October 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top